What happened
Spyre Therapeutics, Inc. (NASDAQ: SYRE) Chief Legal Officer and Corporate Secretary Heidy King-Jones sold 28,933 shares on 2026-10-01.
The Form 4 shows five sale blocks at weighted-average prices from $89.24 to $93.46 per share, totaling about $2.63 million. It also shows a separate 28,933-share option exercise at $14.5 per share, and the filing says full price-by-price details are available on request.
After the reported transactions, King-Jones held 2,845 shares and 482,478 stock options. The option represents the right to purchase 539,810 shares of common stock, adjusted for the company's 1-for-25 reverse stock split on September 8, 2023.
One quarter vested on September 1, 2024, and the remaining three quarters vest monthly over the following three years. The option expires on September 1, 2033, subject to continued employment with the issuer.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 28,933 shares | SEC Form 4 | |
| Sale price range | $89.24 to $93.46 per share | SEC Form 4 | |
| Total sale proceeds | about $2.63 million | SEC Form 4 | |
| Shares held after sale | 2,845 shares | SEC Form 4 | |
| Option exercise | 28,933 shares at $14.5 per share | SEC Form 4 |
Read more: Spyre Therapeutics (SYRE) stock analysis and investment case
Why it matters
OptimistFi's case is that Spyre is a high-risk clinical-stage option on long-acting antibody and antibody-combination drugs. This filing mainly updates insider exposure. OptimistFi's calculation shows the 28,933 shares were about 91.0% of the holding before the trade.
That makes the sale a large reduction in direct ownership. The $2.63 million figure covers the five sale blocks only, not the separate option exercise at $14.5 per share.
The Rule 10b5-1 plan and the 2,845 shares still held afterward keep the filing from reading as a fresh operating signal. King-Jones also still held 482,478 stock options after the transactions.
The filing separates the option exercise from the sale blocks, so the $2.63 million figure covers only the sales.
Browse: stock research on every company OptimistFi covers
What's next
King-Jones still held 2,845 shares and 482,478 stock options after the reported transactions. That leaves the filing's disclosed stake as the baseline for any later sales made under the named plan.
The plan adopted on April 16, 2026 and the option's monthly vesting schedule set the filing's timing context for the remaining position.
More from OptimistFi
- SYRE stock: the Spyre Therapeutics thesis, its status and the next test to watch
- Century Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 Batches
- Applied Digital Corporation (NASDAQ: APLD) Brings 250 MW Online
- ON Semiconductor Corporation (NASDAQ: ON) Cuts Its Deal Cost by 19%
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC Form 4 — Filed 2026-10-02 by Heidy King-Jones
Read the full OptimistFi thesis on Spyre Therapeutics, Inc.: https://optimistfi.com/stocks/SYRE
See what would break the Spyre Therapeutics, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Spyre Therapeutics, Inc. investment case, its status and the next test to watch live on the Spyre Therapeutics, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
